

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

CDF Rapid Reconsideration

**Everolimus for the second-line treatment of metastatic renal cell
carcinoma (review of TA219)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Appraisal Determination

(when no ACD was issued)

| |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
| N/A |

| |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
| No other potential equalities issues have been raised. |

| |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
| No other potential equalities issues have been identified. |

| |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No. |

| |
|---|
| 5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No. |

| |
|---|
| 6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| N/A |

| |
|---|
| 7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| N/A |

Approved by Programme Director (name): Meindert Boysen

Date: 02/03/2017